Skip to main content

Table 2 Frequency of first-line chemotherapeutic regimens and incidence of AE-ILD during first-line chemotherapy

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

 

Bev group (n = 17)

Non-Bev group (n = 31)

Regimens

N

Incidence of AE

N

Incidence of AE

CDDP + PEM

4

0

7

1

CBDCA + PEM

10

0

15

4

PEM

1

0

3

1

CBDCA + PTX

2

0

6

1

Total treatments

17

0

31

7

PEM-containing regimens

15

0

25

6

  1. Data are expressed as number of patients. AE-ILD acute exacerbation of interstitial lung disease, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us